Clinical trial · Observational
Cost-Utility Analysis Hospital Versus Home in Multiple Myeloma
Cost-Utility Evaluation Comparing Hospital Versus Home-Based Bortezomib in Multiple Myeloma: The ADHOMY Study
NCT03493737CI-TRIAL-00046651ADHOMYcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Bortezomib needs repetitive visits at hospital for injections. Hospital-at-Home (HaH) might be an attractive and suitable alternative in this situation. This study aim to perform a cost-utility analysis of two different strategies in several HaH structures within the Grand Est region in France.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Quality of life surveys | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- HaH (Hospital-at-Home)
- description
- Bortezomib is injected at Outpatient hospital at day 1 and at Home at further day of cycles
- interventionNames
- Behavioral: Quality of life surveys
- label
- OH (Outpatient Hospital)
- description
- Bortezomib is always injected at Outpatient hospital
- interventionNames
- Behavioral: Quality of life surveys
Primary outcomes (3)
- measure
- Cost therapy assessment
- timeFrame
- 10 months follow-up per patient
- description
- Cost therapy assessment including direct medical costs, non-medical costs and indirect costs, investigated from the French Health Insurance perspective and expressed in Euro.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Minimum age 18 * Enrolled in a social security scheme * Diagnosis of multiple myeloma in first line or relapse * Treatment plan including Bortezomib, adopted in a multidisciplinary meeting in a department of Hematology in Nancy (main investigator), Reims, Strasbourg University Hospitals or Metz-Thionville and Mulhouse local state-run hospitals * The patients must have agreed to the treatment protocol and to take IV or PO associated drugs prescribed in addition to Bortezomib * The patients must meet the 2003 eligibility criteria of the National Agency for Accreditation and Evaluation in Health (ANAES) for chemotherapy at home: * Absence of severe adaptive or psychological disorders, ability to understand the protocol * Absence of cognitive impairment * Availability and agreement of the attending physician * Home safety and hygiene * Do not decline to participate in the research and share their personal data Exclusion Criteria: * Already participating in another trial * Have a follow-up and/or treatment for another condition requiring a particular care during the Bortezomib treatment period
References
Publications (0)
Data not yet available
No reference posted for this study.